powerpoint presentation - uab...• older women with medical co-morbidities manchester procedure •...

15
1/2/2019 1 Evidence-Based Review of Transvaginal Hysteropexy for Uterovaginal Prolapse Holly E. Richter, PhD, MD J Marion Sims Endowed Chair Professor Obstetrics and Gynecology, Urology and Geriatrics Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology February 21 , 2019 Disclosures Pelvalon-consultant; research funding, device study, non-surgical treatment FI Renovia-consultant; research funding non- surgical treatment SUI Bluewind-consultant, refractory UUI UpToDate Travel with IUJ and Obstet Gynecol, editor NIA-research funding NICHD, NIDDK-research funding PCORI-research funding No Conflict of Interest Objectives Discuss hysteropexy indications -Patient selection -Contraindications To summarize existing evidence regarding objective and subjective outcomes of native tissue hysteropexy techniques vs vaginal hysterectomy for uterovaginal prolapse To present results of most recent RCT of mesh hysteropexy/repairs to TVH/repairs for uterovaginal prolapse: Study of Uterine Prolapse Procedures Randomized Trial (SUPeR)

Upload: others

Post on 09-Jul-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

1/2/2019

1

Evidence-Based Review of Transvaginal

Hysteropexy for Uterovaginal Prolapse

Holly E. Richter, PhD, MD

J Marion Sims Endowed Chair

Professor Obstetrics and Gynecology, Urology and Geriatrics

Division of Urogynecology and Pelvic Reconstructive Surgery

Department of Obstetrics and Gynecology

February 21 , 2019

Disclosures

• Pelvalon-consultant; research funding,

device study, non-surgical treatment FI

• Renovia-consultant; research funding non-

surgical treatment SUI

• Bluewind-consultant, refractory UUI

• UpToDate

• Travel with IUJ and Obstet Gynecol, editor

• NIA-research funding

• NICHD, NIDDK-research funding

• PCORI-research funding

No Conflict of Interest

Objectives

• Discuss hysteropexy indications

-Patient selection

-Contraindications

• To summarize existing evidence regarding

objective and subjective outcomes of native

tissue hysteropexy techniques vs vaginal

hysterectomy for uterovaginal prolapse

• To present results of most recent RCT of mesh

hysteropexy/repairs to TVH/repairs for

uterovaginal prolapse: Study of Uterine Prolapse

Procedures Randomized Trial (SUPeR)

1/2/2019

2

Do We Have to Perform a

Hysterectomy?• Uterus not the cause

• Hysterectomy routinely performed - improve support

• True?

• Standard of care?

• Limited exposure to hysteropexy – residency/

fellowship

• Women request hysteropexy - unique reasons or

preferences/clinical situations

• An increasing number of studies are

investigating uterine sparing procedures with an

emphasis on:

-efficacy

-safety

-improved quality of life

1/2/2019

3

Outcomes of NT Hysteropexy vs Hysterectomy

• Recent systematic review addressing this issue:*

-similar short-term efficacy, 3 years (apical recurrence, RR 2.22, 95% CI, 0.80 to 6.17; anterior, RR 0.86, 95% CI, 0.48 to 1.55; posterior RR 0.79, 95% CI, 0.79 to 2.03

-decreased blood loss (-89.9 mL, 95% CI, -14.9 to -165.0 mL)

-decreased operative time (-17.5 min, 95% CI, -6.0 to -29.2 min)

-satisfaction (RR, 1.07, 95% CI, 0.38 to 2.99)

*Meriwether et al, 2018

Patient Opinions

• 220 referrals prolapse

• 127 (57.5%) response

• 60% choose hysteropexy if equal efficacy

• Hysterectomy: worsen mood, relationship, QOL,

femininity, body image, lubrication, sex drive, weight

gain

• Most important factors:

• Doctor’s opinion

• Risk of surgical complications

• Risk of malignancy

Frick AC et al. Attitudes toward hysterectomy in women undergoing evaluation for uterovaginalprolapse. Female Pelvic Med Reconstr Surg 2013;19:103-9.

So why am I talking about this?

• Do I have something against vaginal

hysterectomy?

• Am I on a crusade to “SAVE THE UTERUS”?

• Do I want to have an evidence-based discussion

with my patients on all surgical options for the

treatment of uterovaginal prolapse?

1/2/2019

4

Why Leave the Uterus?

• Desires future fertility

• Belief that the uterus affects sexual

function or sense of identity

• Concern about risks of hysterectomy

Hysterectomy / Ovarian Function

• Prospective cohort, age 30-47

• Hyst no BSO (406) vs Controls (465)

• Annual blood samples x 5 yrs

• Ovarian failure: FSH ≥ 40

• Hyst: HR = 1.92 (1.29-2.86)

• Hyst only: HR = 1.74 (1.14-2.65)

• Hyst + USO: HR = 2.93 (1.57-5.49)

• 14.8% Hyst vs 8% controls ovarian failure >4 yrs

Moorman PG. Effect of hysterectomy with ovarian preservation on ovarian function. ObstetGynecol 2011;118:1271-9.

Contraindications Uterine Conservation

• Uterine abnormalities

• Fibroids, adenomyosis, endometrial pathology

• Current/recent cervical dysplasia

• Abnormal menses

• PMB

• Genetic risks

• BRCA 1 & 2, HNPCC

• Tamoxifen therapy

• Unable to comply with routine surveillance

1/2/2019

5

Types of Hysteropexy

• Vaginal

– Manchester

– Uterosacral

hysteropexy

– Sacrospinous

hysteropexy

– Vaginal Mesh

hysteropexy

• Abdominal

– Sacral hysteropexy

• Laparotomy

• Laparoscopy

• Robotic

– Laparoscopic

uterosacral

hysteropexy

Types of Hysteropexy

• Vaginal

– Manchester

– Uterosacral

hysteropexy

– Sacrospinous

hysteropexy

– Vaginal Mesh

hysteropexy

• Abdominal

– Sacral hysteropexy

• Laparotomy

• Laparoscopy

• Robotic

– Laparoscopic

uterosacral

hysteropexy

1/2/2019

6

Manchester Procedure

• First described in 1888 by McDonald and

modified by Fothergill, 1921

• Primarily a procedure for cervical elongation

(cervical amputation followed by midline cardinal

and uterosacral ligament plication)

• Premenopausal women to maintain fertility

• Older women with medical co-morbidities

Manchester Procedure

• Only RCT, Ünlübiligin et al, 2013

• Primary outcome, prolapse recurrence 5 years

defined as point C>-1

• 49 MP vs 45 TVH

• No difference between groups at baseline, point C

(0.77±0.75, MP vs 1.31±0.51, TVH p=0.062)

• No difference 5 years, (-6.3±0.91 MP vs -6.0±0.97

TVH, p=0.13)

• MP, shorter operative time, p=0.003 and shorter

hospital stay, p=0.042)

Manchester Procedure vs TVHStudy Design Surgeries Number

of Patients

Success

Rate

Follow

Up

Success

Definition

Outcome

measures

Thys et al

(2011)

Retrospective

matched cohort

MP vs. TVH

with USLS

MP: 98

TVH: 98

MP: 81%

TVH: 82%

Median 6

years

No

recurrence of prolapse

on exam

(unclear)

QOL,

morbidity, POP recurrence

Iliev (2014) Retrospective

matched cohort

MP vs. TVH MP: 33

TVH: 33

MP: 90%

TVH: 85%

1 year No

retreatment of prolapse

(unclear)

POP

recurrence, re-treatment,

complications,

operative time,

EBL

Kalogirou

(1996)

Retrospective

cohort

MP vs. TVH

with AR

MP: 190

TVH: 231

MP: MD

TVH: MD

3 years No

anatomic outcomes

Operative time,

EBL, hospital stay

De Boer et

al (2009)

Retrospective

cohort

MP vs. TVH

with USLS

MP: 81

TVH: 75

MP: 100%

TVH: 96%

1 year POPQ point

C (Stage 1 or less)

POPQ points,

operative time, EBL, hospital

stay

Thomas et

al (1995)

Retrospective

cohort

MP vs. TVH MP: 88

TVH: 105

MP: MD

TVH: MD

No follow

up

No

anatomic outcomes

Operative time,

EBL, hospital stay

1/2/2019

7

Skiadas CC, et al, The Manchester-Fothergill Procedure as a Fertility Sparing Alternative

for Pelvic Organ Prolapse in Young Women. J Pediatr Adolesc Gynecol 2006;19:89-93.

Manchester Procedure

Skiadas CC, et al, The Manchester-Fothergill Procedure as a Fertility Sparing Alternative

for Pelvic Organ Prolapse in Young Women. J Pediatr Adolesc Gynecol 2006;19:89-93.

Manchester Procedure

Skiadas CC, et al, The Manchester-Fothergill Procedure as a Fertility Sparing Alternative

for Pelvic Organ Prolapse in Young Women. J Pediatr Adolesc Gynecol 2006;19:89-93

Manchester Procedure

1/2/2019

8

Uterosacral Hysteropexy

• No RCTs comparing outcomes of USH and TVH

• Romanzi et al, 2012 retrospective cohort

• Primary outcome ≥Grade 2 prolapse any

compartment; N=100 each group

• No difference in baseline anterior or apical

compartments (point C, 2.91±0.91, USH vs

2.84±1.02, TVH, p=0.82)

• No difference in 2 year recurrence-free durability

apex: (96%, 95% CI, 87.7%, 98.8%), p=0.90

Uterosacral Hysteropexy

Sacrospinous Hysteropexy

• Best studied vaginal uterine-sparing procedure

• SSLF of the vaginal cuff first described in 1950’s

• Richardson et al, reported a case series of 5

patients in 1989

Richardson, Scotti, Ostergard, JRM, 1989

1/2/2019

9

Sacrospinous Hysteropexy

Richardson DA, et al. Surgical Management of Uterine Prolapse in Young Women. J

Reprod Med 1989;34:388-92.

Sacrospinous Hysteropexy

• Unilateral • Bilateral

Kovac SR, Cruikshank SH. Successful pregnancies and vaginal deliveries after

sacrospinous uterosacral fixation in five of nineteen patients. Am J Obstet Gynecol

1993;168:1778-86.

Sacrospinous Hysteropexy

1/2/2019

10

Cohort Studies SSH vs HysterectomyStudy Design Surgery Number of

Patients

Success Rate Follow Up Success Definition

Hefni et al

(2003)24

Prospective

cohort

SSH vs TVH

with SSLF

SSH: 61

TVH: 48

SSH: 94%

TVH: 96%

33 months Apex greater than

6cm from hymen on valsalva

Maher et al

(2001)25

Retrospective

cohort

SSH vs TVH

with SSLF

SSH: 34

TVH: 36

SSH: 74%

TVH: 72%

26 months Apex above ½ TVL,

no repeat surgery

Van

Brummen (2003)26

Retrospective

cohort

SSH vs TVH

with USLS

SSH: 44

TVH: 30

SSH: 89%

TVH: 93%

19 months Baden-Walker grade

1 or less of any compartment

Lo et al

(2015)27

Retrospective

cohort

SSH vs TVH

with SSLF

SSH: 26

TVH: 120

SSH: 50%

TVH: 72%

86 months POPQ Stage 1 or

less

Sacrospinous Hysteropexy

• Dietz 2010

• RCT SSH (n=37) vs. TVH, USLS (n=34)

• Apical recurrences: 21% vs. 3%, p=0.03

• 3 SSHP stage 4 prolapse – all failed

• Subjective: both improved

• Shorter LOS, quicker return work, longer TVL

• Anterior prolapse (51% vs. 64%)

Dietz V, et al. One-year follow-up after sacrospinous hysteropexy and vaginal

hysterectomy for uterine descent: a randomized study. Int Urogynecol J 2010;21: 209-16

Sacrospinous Hysteropexy

• Detollenaere, et al, 2015

• Non-inferiority RCT

• N=103, SSH vs N=105, TVH/USLS

• 1° outcome-composite at 12 months (apical <

Stage 2, no bothersome symptoms and no re-op)

• Success: 100% SSH vs 96% TVH, (-3.9, 95% CI,

-8.6, 0.7)

• Functional and QOL similar

• AEs: Buttock pain, 9% vs 0%

Detollenaere et al, BMJ, 2015

1/2/2019

11

Sacrospinous Hysteropexy

• Jeng 2005

• RCT, SSH vs TVH/SSLF

• No difference sexual function (FSFI-7)

• Low rate dyspareunia (5%)

• No anatomic outcomes

• Transient buttock pain (15%)

Jeng CJ, et al. Sexual functioning after vaginal hysterectomy or transvaginal sacrospinous uterine suspension for uterine prolapse: a comparison. J Reprod Med 2005; 50:669-74

Vaginal Mesh Hysteropexy

Vaginal Mesh Hysteropexy

1/2/2019

12

UpholdTM Hysteropexy

UpholdTM Hysteropexy

• 115 total, 53 HP

• Follow-up 12 mo

• POP-Q Preop Postop p

• Ba 0.9 -2.4 <0.01

• C -2.4 -7.7 <0.01

• Bp -0.1 -2.6 <0.01

• 1(1.9%) apical recurrence, no anterior (POPQ ≤ 1)

• 1 (1.9%) mesh exposure, no pain/dyspareunia

Vu MK, et al. Int Urogynecol J, 2012

Study of Uterine Prolapse Procedures

Randomized Trial (SUPeR), NCT01802281

• RCT : Apical Uphold Mesh Hysteropexy/Repairs vs TVH/Repairs

• Primary Outcome 36 months, survival models

• Composite outcome: no prolapse symptoms, no prolapse beyond the hymen, no retreatment

• N=175 total, mean age 65.9±0.6

• No difference in primary outcome, aHR 0.65, 95% CI 0.39, 1.06

• Operative times significantly shorter in HSP group, 111.5±4.2 min vs 156.7±4.7 min, p<0.0001

• POPQ point Ba, HSP -1.2±0.1 vs TVH 0.7±0.2, p=0.03

• Mesh exposure 8%

• Functional and QOL similar

Nager et al, FPMRS 2016

1/2/2019

13

Pregnancy and Hysteropexy

• Pessary first line

• Limited information counselling patients desiring

future pregnancy

• No data regarding which hysteropexy better for:

• Fertility

• Pregnancy & delivery

• Postpartum support & durabilityCavkaytar et al, 2017

How Do I Choose a Vaginal Uterine-Sparing

Approach?• Desires future fertility

• Vaginal SSH

• Completed childbearing and sexually active

• Vaginal SSH, TV mesh hysteropexy

• Done with childbearing and not sexually active

• LeFort Colpocleisis

• Other obliterative approach (SSH/obliterative

closure)

1/2/2019

14

Conclusion• Uterine conservation is a reasonable option and

would discuss all options with patients

• Proper patient selection

• Limited long-term data

• Subsequent hysterectomy may be challenging

• Currently not standard of care-increasingly being

offered and performed

• Better results: data would support mesh anterior

compartment; need longer term outcomes of RCTs

• Risk failure: Stage 4/cervical elongation

For more information on active

studies

Please visit our Urogynecology table:

Kathy Carter, RN, BSN

Jill Hyde, RN, BSN

Robin Willingham, RN, BSN

Call: 205-934-5498

Select References• Korbly NB, Kassis NC, Good MM, et al. Patient preferences for uterine preservation

and hysterectomy in women with pelvic organ prolapse. Am J Obstet Gynecol

2013;209:470.e1-6.

• Madsen AM, Raker C, Sung VW. Trends in hysteropexy and apical support for

uterovaginal prolapse in the United States from 2002 to 2012. Female Pelvic Med

Reconstr Surg 2017;23: 365-371

• Meriwether KV, Antosh DD, Olivera et al. Uterine preservation vs hysterectomy in

pelvic organ prolapse surgery: a systematic review with meta-analysis and clinical

practice guidelines. Am J Obstet Gynecol 2018; 219(2):129-146

• Ünlübilgin E, Sivaslioglu AA, Ilhan TT, Kumtepe Y, Dölen I. Which one is the

appropriate approach for uterine prolapse: Manchester procedure or vaginal

hysterectomy? Turkiye Klinik J Med Sci 2013;33:321-5

• Romanzi, L.J., Tyagi, R. Hysteropexy compared to hysterectomy for uterine prolapse

surgery: does durability differ?. Int Urogynecol J. 2012;23:625–631

• Richardson DA, Scotti RJ, Ostergard DR. Surgical management of uterine prolapse in

young women. J Reproduc Med. 1989 Jun;34(6):388-92

• Dietz, V., van der Vaart, C.H., van der Graaf, Y., Heintz, P., Schraffordt Koops, S.E.

One-year follow-up after sacrospinous hysteropexy and vaginal hysterectomy for

uterine descent: a randomized study. Int Urogynecol J. 2010;21:209–216

1/2/2019

15

Select References• Detollenaere, R.J., den Boon, J., Stekelenburg, J. et al, Sacrospinous hysteropexy vs vaginal

hysterectomy with suspension of the uterosacral ligaments in women with uterine prolapse stage 2 or higher: multicentre randomised non-inferiority trial. BMJ. 2015;351:h3717

• Jeng, C.J., Yang, Y.C., Tzeng, C.R., Shen, J., Wang, L.R. Sexual functioning after vaginal

hysterectomy or transvaginal sacrospinous uterine suspension for uterine prolapse: a comparison.

J Reprod Med. 2005;50:669–674

• Maher, C.F., Cary, M.P., Slack, M.C., Murray, C.J., Milligan, M., Schluter, P. Uterine preservation or

hysterectomy at sacrospinous colpopexy for uterovaginal prolapse?. Int Urogynecol J Pelvic Floor

Dysfunct. 2001;12:381–384 (discussion 384-5)

• Lo, T.S., Pue, L.B., Hung, T.H., Wu, P.Y., Tan, Y.L. Long-term outcome of native tissue

reconstructive vaginal surgery for advanced pelvic organ prolapse at 86 months: Hysterectomy vs

hysteropexy. J Obstet Gynaecol Res. 2015;41:1099–1107

• Maher, C., Baessler, K., Glazener, C.M., Adams, E.J., Hagen, S. Surgical management of pelvic organ prolapse in women: a short version Cochrane review. Neurourol Urodyn. 2008;27:3–12

• Cavkaytar S, Kokanalı MK, Tasdemir U, Doganay M, Aksakal O. Pregnancy outcomes after

transvaginal sacrospinous hysteropexy. Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:204-207

• Nager CW, Zyczynski H, Rogers RG, Barber MD, Richter HE, Visco AG, Rardin CR, Harvie H,

Wallace D, Meikle SF; Pelvic Floor Disorders Network. The Design of a Randomized Trial of

Vaginal Surgery for Uterovaginal Prolapse: Vaginal Hysterectomy With Native Tissue Vault

Suspension Versus Mesh Hysteropexy Suspension (The Study of Uterine Prolapse Procedures

Randomized Trial). Female Pelvic Med Reconstr Surg. 2016 Jul-Aug;22(4):182-9